DBRC
BMRN icon

D.B. Root & Company’s BioMarin Pharmaceuticals BMRN Stock Holding History

D.B. Root & Company’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,011
Closed -$350K – 185
2024
Q1 		$350K Hold
4,011
– – 0.12% 139
2023
Q4 		$387K Sell
4,011
-395
-9% -$34.9K 0.14% 127
2023
Q3 		$390K Buy
4,406
+33
+0.8% +$2.94K 0.15% 123
2023
Q2 		$379K Buy
4,373
+290
+7% +$27.3K 0.14% 133
2023
Q1 		$397K Buy
4,083
+1
+0% +$104 0.16% 122
2022
Q4 		$422K Sell
4,082
-299
-7% -$28.1K 0.18% 115
2022
Q3 		$371K Sell
4,381
-7
-0.2% -$623 0.17% 116
2022
Q2 		$363K Sell
4,388
-3,223
-42% -$257K 0.16% 128
2022
Q1 		$586K Buy
7,611
+34
+0.4% +$2.85K 0.22% 111
2021
Q4 		$669K Sell
7,577
-152
-2% -$12.5K 0.24% 106
2021
Q3 		$597K Sell
7,729
-1,521
-16% -$120K 0.23% 110
2021
Q2 		$771K Sell
9,250
-82
-0.9% -$6.5K 0.29% 96
2021
Q1 		$704K Buy
9,332
+2,336
+33% +$191K 0.28% 96
2020
Q4 		$613K Sell
6,996
-26
-0.4% -$2.06K 0.24% 105
2020
Q3 		$534K Buy
7,022
+783
+13% +$79.2K 0.21% 122
2020
Q2 		$769K Sell
6,239
-220
-3% -$21.9K 0.33% 81
2020
Q1 		$545K Buy
6,459
+275
+4% +$23.7K 0.28% 92
2019
Q4 		$522K Buy
6,184
+2,260
+58% +$171K 0.23% 120
2019
Q3 		$264K Sell
3,924
-175
-4% -$13.5K 0.12% 171
2019
Q2 		$351K Sell
4,099
-45
-1% -$3.85K 0.16% 155
2019
Q1 		$368K Buy
4,144
+394
+11% +$36.5K 0.16% 150
2018
Q4 		$319K Sell
3,750
-2,800
-43% -$266K 0.16% 147
2018
Q3 		$635K Sell
6,550
-2,110
-24% -$211K 0.28% 108
2018
Q2 		$816K Buy
8,660
+345
+4% +$30.2K 0.39% 91
2018
Q1 		$674K Buy
+8,315
New +$714K 0.36% 96

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

D.B. Root & Company's BMRN Position: Q2 2024 in Review

D.B. Root & Company sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 4,011 shares — an estimated $350K sold.

D.B. Root & Company first reported a position in BMRN in Q1 2018 and held it in 25 quarters. The position peaked at $816K in Q2 2018. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

  • D.B. Root & Company reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • D.B. Root & Company sold 4,011 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $350K.
  • D.B. Root & Company first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 25 quarters.
  • D.B. Root & Company's BioMarin Pharmaceuticals position peaked at $816K in Q2 2018.
  • 558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on D.B. Root & Company's 13F filing for Q2 2024, filed 15 Jul 2024.